金斯瑞生物科技(01548)：CARVYKTI于截至2025年9月30日止季度产生贸易销售净额约5.24亿美元

Core Viewpoint - Kingsray Biotechnology (01548) announced that CARVYKTI® is projected to generate trade sales net revenue of approximately $524 million for the quarter ending September 30, 2025, based on the collaboration and licensing agreement established with Janssen Biotech, Inc. on December 21, 2017 [1] Summary by Category - Company Performance - CARVYKTI® is expected to achieve net trade sales of about $524 million by the end of Q3 2025 [1] - Partnerships - The revenue projection is based on the collaboration and licensing agreement with Janssen Biotech, Inc. signed on December 21, 2017 [1]